<Daily Summary> HSI Ends at 25,530, Decreasing by 10 Points; HSTI Finishes at 5,534, Down 46 Points; ALI HEALTH Falls More Than 3%; HANSOH PHARMA Reaches New Highs; Market Turnover Increases

The analyst rating from CLSA for JD Health and Alibaba Health is maintained at "Outperform" due to a positive outlook for next year's growth in pharmaceutical sales and margin expansion. Despite projecting conservative guidance for 4Q25 based on a trade-in base effect, CLSA forecasts double-digit revenue growth for both companies next year, with JD Health expected to grow at a faster pace. The target price for JD Health is set at HK$71, while Alibaba Health's target price is trimmed to HK$6 to reflect a slower growth outlook.

The analyst rating for ALI HEALTH (00241.HK) is maintained at Neutral by JPMorgan due to a combination of factors. The company achieved strong revenue growth of 17% in 1HFY2026, primarily driven by the growth of originator drugs and structural changes in China's pharmaceutical market. However, there is uncertainty regarding the sustainability and incremental contribution of Taobao's instant retail, which could affect future sales growth. As a result, while the current momentum is positive, the broker advises caution and highlights the need to monitor fluctuations in instant retail subsidies and potential user churn. The target price is set at $6.5 based on a projected 2.5x EV/revenue multiple for FY2026.

Goldman Sachs maintained a Neutral rating on ALI HEALTH (00241.HK) due to several key factors. The company is benefiting from structural industry tailwinds, such as the shift of original drugs from in-hospital channels and the growth of online drug sales. However, there is a noted divergence in revenue growth between ALI HEALTH and its competitor JD HEALTH, with ALI HEALTH lagging in establishing a comprehensive first-party (1P) business model, particularly in user awareness and supply chain capabilities. Despite this, Goldman Sachs sees potential upside in ALI HEALTH's results guidance for FY2026, driven by strong growth in its 1P platform sales and effective cost control. The target price was raised from $4.7 to $5.2, reflecting a 2027 PE ratio of 28x for its pharmacy and healthcare services projections.